Latest news : Gamida Cell Ltd.

27/05/25	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/07/24	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/06/24	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/06/24	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/06/24	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/06/24	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24/05/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/04/24	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/04/24	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/03/24	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/03/24	Top Premarket Decliners	MT
27/03/24	Top Midday Decliners	MT
27/03/24	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations: Gamida Cell Ltd.

29/01/24	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/11/23	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/11/23	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/05/23	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/05/23	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases: Gamida Cell Ltd.

27/03/24	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/03/24	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/03/24	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/02/24	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/01/24	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors: Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Ronit Simantov CTO	Chief Tech/Sci/R&D Officer	61	01/07/2017

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets Other stock markets 20:54:51 24/05/2024 +04			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	2.62M 2.29M 2.11M 1.95M 3.7M 250M 3.76M 25.24M 9.91M 123M 9.83M 9.62M 423M	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	39.01M 34.12M 31.47M 29.07M 55.15M 3.72B 56.08M 376M 148M 1.83B 146M 143M 6.3B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.62
5 years	0.01	6.03
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
31/01/24	Kenneth Moch	Free	Director	200,000	0.1508%
31/01/24	Stephen Wills	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.94%	2.62M
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+59.82%	+92.96%	54.88B
ARGENX SE	-4.14%	-8.06%	+58.96%	+118.67%	54.63B
INSMED INCORPORATED	-2.24%	+3.59%	+17.75%	+477.47%	25.06B
BIONTECH SE	-1.60%	-6.21%	-18.96%	-15.21%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+42.44%	-1.27%	19.87B
GENMAB A/S	-3.19%	0.00%	+35.60%	-26.98%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	16.5B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+51.91%	+726.40%	15.75B
EXELIXIS, INC.	-1.05%	+1.16%	+25.95%	+194.27%	14.2B
Average	-0.36%	+0.12%	+46.86%	+182.45%	24.16B
Weighted average by Cap.	-0.89%	-1.45%	+51.26%	+177.13%

Gamida Cell Ltd. Stock

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation: Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

	2022	2023
Net sales	-	1.78 1.56 1.44 1.33 2.52 170.15 2.56 17.2 6.75 83.82 6.7 6.55 288.16
Net income	-79.38M -69.43M -64.04M -59.15M -112M -7.57B -114M -765M -300M -3.73B -298M -292M -12.82B	-63M -55.1M -50.83M -46.94M -89.07M -6.01B -90.57M -607M -238M -2.96B -237M -231M -10.18B
Net Debt	39.31M 34.38M 31.71M 29.29M 55.58M 3.75B 56.51M 379M 149M 1.85B 148M 144M 6.35B	36.39M 31.83M 29.36M 27.12M 51.45M 3.47B 52.32M 351M 138M 1.71B 137M 134M 5.88B